Your browser doesn't support javascript.
loading
How inclusive were UK-based randomised controlled trials of COVID-19 vaccines? A systematic review investigating enrolment of Black adults and adult ethnic minorities.
Herieka, Hibba; Babalis, Daphne; Tzala, Evangelia; Budhathoki, Shyam; Johnson, Nicholas A.
Afiliação
  • Herieka H; University of Leicester Medical School, University of Leicester, Leicester, UK.
  • Babalis D; Imperial Clinical Trials Unit, School of Public Health, Faculty of Medicine, Imperial College London, Stadium House, 68 Wood Lane, London, W12 7RH, London, UK.
  • Tzala E; School of Public Health, Faculty of Medicine, Imperial College London, London, UK.
  • Budhathoki S; School of Public Health, Faculty of Medicine, Imperial College London, London, UK.
  • Johnson NA; Imperial Clinical Trials Unit, School of Public Health, Faculty of Medicine, Imperial College London, Stadium House, 68 Wood Lane, London, W12 7RH, London, UK. nicholas.johnson@imperial.ac.uk.
Trials ; 25(1): 255, 2024 Apr 12.
Article em En | MEDLINE | ID: mdl-38605411
ABSTRACT

OBJECTIVES:

To establish if Black adults and adult ethnic minorities, defined as any group except White British, were represented in UK-based COVID-19 vaccination randomised controlled trials (RCTs) when compared to corresponding UK population proportions, based on 2011 census data.

DESIGN:

Systematic review of COVID-19 Randomised Controlled Vaccine Trials

SETTING:

United Kingdom

PARTICIPANTS:

Randomised Controlled Trials of COVID-19 vaccines conducted in the UK were systematically reviewed following PRISMA guidelines. MeSH terms included "Covid-19 vaccine", "Ad26COVS1", and "BNT162 Vaccine" with keywords such as [covishield OR coronavac OR Vaxzevria OR NVX-CoV2373] also used. Studies that provided (A) participant demographics and (B) full eligibility criteria were included. The following key data was extracted for

analysis:

number of participants analysed, number of Black adults and number of adult minority ethnicity participants. PRIMARY AND SECONDARY OUTCOME

MEASURES:

The primary outcome is the mean percentage of Black adults randomised to COVID-19 vaccine trials deemed eligible within this review. The secondary outcome is the mean percentage of adult ethnic minorities randomised.

RESULTS:

The final review included 7 papers and a total of 87 sets of data collated from trial sites across the UK. The standard mean percentage of Black adults included in the trials (0.59%, 95% CI 0.13% - 1.05%) was significantly lower compared to the recorded Black adult population (2.67%) indicating that they were under-served in UK based COVID-19 vaccine RCTs (p < 0.001). Adult ethnic minority presence (8.94%, 95% CI 2.07% - 15.80%) was also lower than census data (16.30%), indicating they were also under-served (p = 0.039).

CONCLUSION:

The findings show that COVID-19 vaccine trials failed to adequately randomise proportionate numbers of Black adults and adult minority ethnicities. More inclusive practices must be developed and implemented in the recruitment of underserved groups to understand the true impact of COVID-19.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinas contra COVID-19 / COVID-19 Limite: Adult / Humans País/Região como assunto: Europa Idioma: En Revista: Trials Assunto da revista: MEDICINA / TERAPEUTICA Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinas contra COVID-19 / COVID-19 Limite: Adult / Humans País/Região como assunto: Europa Idioma: En Revista: Trials Assunto da revista: MEDICINA / TERAPEUTICA Ano de publicação: 2024 Tipo de documento: Article